drugset / Trial / NCT00280683
Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma
Phase 2
Completed
20 enrolled
University of California, Davis
National Center for Research Resources (NCRR) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a protective role in patients with moderate to severe asthma. The investigators believe that a natural amino acid, L-arginine, that augments nitric oxide levels can decrease asthma exacerbations and improve the asthma care of moderate to severe asthma patients. This study is a randomized, placebo controlled trial in which subjects will receive either 3 months of L-arginine supplementation or a placebo. The investigators will monitor subjects' symptoms, the number of asthma exacerbations, and lung function. In addition, we will draw blood, obtain induced sputum samples and measure exhaled breath nitric oxide levels at each monthly visit.
Timeline
- Start
- 2004-12
- Primary completion
- 2008-11
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | L-arginine | Small molecule | 0.01 g/kg | Oral |
| Comparator | L-arginine | Small molecule | 0.1 g/kg | Oral |